secwatch.observer — SEC 8-K summary
======================================

Issuer:     Semnur Pharmaceuticals, Inc. (SMNR)
CIK:        0001913577
Form:       8-K
Filed at:   2023-08-04T23:59:59+00:00
Accession:  0001213900-23-063189
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Capital files updated investor presentation for proposed merger with Longevity Biomedical
--------------------------------------------------------------------------------

- Exhibit 99.1 is an August 2023 investor presentation for the business combination with Longevity Biomedical, superseding the January 2023 version.
- The presentation will be used in meetings with investors; no specific new deal terms or financial projections are disclosed in the filing.
- Upon closing, each of Denali and Longevity will become wholly-owned subsidiaries of Holdco, renamed Longevity Biomedical, Inc.
- The transaction remains subject to regulatory and stockholder approvals; the registration statement was filed on March 29, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1913577/000121390023063189/0001213900-23-063189-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1913577/000121390023063189/ea182794-8k425_denali.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-063189

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer